Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Consumer Discretionary · ·
$0.75
▲ $0.00 (+0.1%)
Market data updated: 09/20 06:33 AM
News analyzed: 09/20/2026
Market Cap
$1.24B
Day Range
$0.75 - $0.78
52-Week Range
$0.73 - $2.50
Beta
—
Next Earnings
—
Support
$0.73
Resistance
$1.64
AHG is a stock from the Consumer Cyclical sector — Retail, automotive, and leisure — demand rises and falls with economic sentiment and consumers' disposable income.
-60.0% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 1/13 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
MACD
MACD histogram is positive — rising momentum
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 13.2% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
32
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
19
Risk
34
Sentiment
62
Fundamental
No data available
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Akso Health Group ADS** has primarily focused on its stock performance and financial signals. Analysts highlight its oversold RSI levels, suggesting potential undervaluation and buying opportunities in the healthcare sector. Additionally, a recent audit raised a "going concern" risk despite improved profitability, prompting an 8.2% stock increase. The company’s shares have also moved alongside broader market trends, reflecting mixed investor sentiment.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Akso Health Group ADS. News trend score: 62. Reason: 5 of the last 8 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
30
🎯 Conviction (vs. Emotion)
50
Psychology
100
Fundamentals
—
Technical
19
Valuation
—
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-44%
Market Narrative
37
Fundamental Reality
50
Narrative Gap
-13
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for AHG is dominated by **loss aversion**, as the stock’s steep 36.7% drop over three months and subdued volume signal investors prioritizing damage control. Herding is also pronounced, with AHG’s decline aligning closely with peers, suggesting passive following rather than independent action. Anchoring near support (0.9% above) may reinforce reluctance to sell further, while the absence of euphoria or overconfidence confirms a risk-averse stance. The key open question is whether the stock’s proximity to support will trigger defensive buying or if further declines will deepen loss aversion, pushing prices lower.
Updated: 09/09/2026, 01:06 AM
What could change this?
👥 What the crowd believes
"Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering undervalued buying opportunities."
"AHG... gain[ed]... in Wednesday’s pre-market session"
"Akso Health Group (AHG) Is Up 8.2% After Auditor Flags Going Concern Risk"
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 96/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The methodologies here split sharply between bullish, neutral, and bearish views on AHG, reflecting stark differences in their core principles. The top three—Samuel Armstrong Nelson, Charles Mackay, and Howard Marks (Market Cycle)—all score near perfection (94–96) because they focus on market psychology, cycle positioning, and crowd behavior, all of which suggest AHG isn’t overbought or manic. Meanwhile, Jack Schwager’s disciplined, reward/risk-driven approach still sees value (76), while Howard Marks (fundamental) and Veblen (growth vs. profit) remain cautiously mixed, hinting at potential overvaluation or mispricing. The bottom half—especially Morgan Housel, Loeb, and Livermore—reject AHG outright, with Housel flagging volatility as a psychological trap, Loeb warning of excessive risk, and Livermore’s trend-following rule dismissing it outright. The middle tier (Graham, Fisher, Lynch, etc.) lacks sufficient data to form a definitive view, leaving AHG as a stock where subjective interpretation dominates.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 96
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 95
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 94
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 76
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 63
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 50
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 38
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 30
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 21
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 10 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 5 positive, 0 neutral, 3 negative out of the last 8 articles.
Benzinga · 16.9.2026
Benzinga · 15.9.2026
Benzinga · 3.9.2026
Benzinga · 20.8.2026
Benzinga · 19.8.2026
Benzinga · 19.8.2026
Benzinga · 18.8.2026
Simply Wall St. · 31.7.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Akso Health Group ADS (AHG) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for AHG specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
AHG's technical score is 19/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: ATR: 13.2% of price; Calmar: -0.16 (3y annualized return -11.7% / max drawdown 75.3%); Price is below the 50-day average.
StockIQ has no recorded dividend payment history for AHG.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 0 filings.
No recent insider transaction filings found for this stock.
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
19,570 shares short as of 2026-08-31 · vs. 23,197 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
17.4% of trading volume this week was short selling, vs. 38.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology